ClinicalTrials.gg
RecruitingNCT06485700PT4AUpdated Feb 27, 2026

Peers and Technology for Adherence, Access, Accountability, and Analytics (PT4A)

An interventional study of Peer Delivery of Medications and Health Information Technology (HIT) Platform in Cardiovascular Disease and Hypertension, sponsored by NYU Langone Health. Recruiting at 3 sites in Kenya. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Primary conditionHypertensionRegistry: Cardiovascular DiseasesReclassifiedWhy we changed it
Registry
Cardiovascular Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypertension
Why
  1. The study's listed conditions name Hypertension, a narrower term within Cardiovascular Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by NYU Langone Health · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Hypertension by NYU Langone Health — 6 open to participants now, 7 under way, none of them phase 3. Hypertension · NYU Langone Health.

Planned enrollment
3rd of 39
1,140 · median 300
Started
2025
with 2 others
No phase
31 of 44
6 open now
Registered
40th of 44
by date

Among the 44 studies in Hypertension by NYU Langone Health, this one is the 3rd largest by planned enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2025, is one of 31 with no phase, and was the 40th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 44 studies in Hypertension by NYU Langone Health are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Hypertension by NYU Langone Health, or all of them as a file.
02

Study summary

Peer-based medication delivery decreases the cost of transportation and the opportunity cost of travel while HIT can support peer activities by facilitating targeted adherence counseling, teleconsultation, synchronization of clinical care, and pharmacy activities. The investigators have implemented a pilot program of door-to-door peer-based medication delivery and HIT in western Kenya, and preliminary data indicate improved adherence and blood pressure. However, the effectiveness of this implementation strategy is not fully established. Therefore, the objective of the study is to use the PRECEDE-PROCEED framework to conduct transdisciplinary implementation research to test the hypothesis that integrating peer delivery of medications with HIT (PT4A) improves medication adherence and reduces blood pressure among patients with uncontrolled hypertension in western Kenya.

Read the detailed description

Aim 1 will evaluate the effectiveness of PT4A by conducting a two-arm cluster randomized controlled implementation research hybrid type 2 trial, comparing PT4A to control. The primary biological outcome is one-year change in systolic blood pressure. The primary adherence outcome is the pill count adherence ratio. The primary implementation outcome is fidelity. Secondary outcomes are blood pressure control, self-reported adherence, and RE-AIM metrics. Aim 2 will evaluate potential mechanistic relationships between implementation measures and outcomes. Sub Aim 2.1 will evaluate if trust in the health system and patient activation mediate the relationship between PT4A and the outcomes. Aim 3 will consist of cost-effectiveness, budget impact, and qualitative analyses to help inform adaptation of PT4A to other settings. The research will be conducted by a transdisciplinary team with diverse and complementary expertise. The investigators intend to add to existing knowledge of innovative and scalable strategies to improve medication adherence for global hypertension control.

03

Conditions studied

  • Cardiovascular Disease
  • Hypertension

Browse trials for

04

In context

Hypertension Reclassified

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

This study's planned enrollment of 1,140 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

NYU Langone Health is the lead sponsor of 1,431 studies on the registry; 258 are open to participants now.

Of its 235 completed or terminated interventional studies of FDA-regulated products, 197 (84%) have results posted.

Compared within Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cardiovascular Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants enrolled in AMPATH's CDM Program with uncontrolled hypertension (SBP ≥ 140 or diastolic BP (DBP) ≥ 90)

Exclusion criteria

Exclusion Criteria:

  • hypertensive emergency requiring immediate medical attention,
  • terminal illness, and
  • inability to provide .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,140 participants (estimated)

Study arms

  • Experimental
    PT4A

    Peer delivery of medications supported by Health Information Technology (HIT) platform.

    Other: Peer Delivery of Medications · Other: Health Information Technology (HIT) Platform

  • No intervention
    Control

    Participants in the control arm will receive the standard of care for hypertension or the standard of care including peer-delivery of medication.

Interventions

  • OtherPeer Delivery of Medications

    Door-to-door peer delivery of medications within patients' communities will be implemented.

  • OtherHealth Information Technology (HIT) Platform

    The HIT platform provides: 1) tailored counseling strategies through decision support; 2) teleconsultation support for clinician-peer-patient interactions; 3) medication refill tracking to enhance accountability of the peer delivery process; and 4) analytics to improve medication supply chain by generating patient-level drug consumption data.

07

What researchers measure

Primary outcomes

  1. Mean Change in SBP from Baseline to Month 12

    Time frame: Baseline, Month 12

  2. Pill Count Adherence Ratio (PCAR) at Month 12

    PCAR is calculated as the percentage of pills taken over the previous month and is measured over a 30-day time period.

    Time frame: Month 12

  3. Number of Patient E-Signatures

    Measure of fidelity.

    Time frame: Up to Month 12

  4. Number of Completed HIT Forms

    Measure of fidelity.

    Time frame: Up to Month 12

Secondary outcomes

  1. Mean Change in SBP from Baseline to Month 6

    Time frame: Baseline, Month 6

  2. Percentage of Participants with Controlled Blood Pressure (BP) at Month 6

    BP measured using automatic BP monitor.

    Time frame: Month 6

  3. Percentage of Participants with Controlled BP at Month 12

    BP measured using automatic BP monitor.

    Time frame: Month 12

08

Study locations

3 of 3 sites recruiting
  • Study Site
    Webuye, Bungoma County, Kenya
    Recruiting
  • Study Site
    Kitale, Trans Nzoia County, Kenya
    Recruiting
  • Study Site
    Eldoret, Uasin Gishu County, Kenya
    Recruiting
09

References and documents

Individual participant data

Plan to share: Yes — The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: Rajesh.vedanthan@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research

Access criteria: The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to Rajesh.vedanthan@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Mar 2028, 28 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 28 months is above that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2024
First posted
Jul 3, 2024
StartActual
Nov 18, 2025
Primary completionEst.
Mar 31, 2028
CompletionEst.
Apr 20, 2028
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06485700
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Jul 3, 2024
Start date
Nov 18, 2025
Primary completion
Mar 31, 2028 (estimated)
Completion
Apr 20, 2028 (estimated)
Last update
Feb 27, 2026

Study contacts

Rajesh Vedanthan
Contact
Rajesh.vedanthan@nyulangone.org
1-646-501-3890
Jessica Gjonaj
Contact
Jessica.gjonaj@nyulangone.org
1-646-501-3663
Rajesh Vedanthan
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion